Trial Profile

Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with translational research to predict efficacy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

22 Sep 2020 Results (n=101) of exploratory analysis assessing predictive markers for patients with KRAS exon wild-type mCRC treated in this trial published in the Targeted Oncology
25 Jan 2020 Results of analysis of early tumor shrinkage and depth of response (n=87) presented at the 2020 Gastrointestinal Cancers Symposium.
29 Aug 2016 Status changed from recruiting to completed according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com